Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity (Frontiers in Oncology, (2020), 10, (1012), 10.3389/fonc.2020.01012)

An author name was incorrectly spelled as “Maria De Filippo”. The correct spelling is “Maria Rosaria De Filippo”. In the published article, there was also an error in affiliation 1. Instead of “Department of BioMedical Research, University of Bern, Bern, Switzerland”, it should be “Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland”. There was also an error in the text. The concentration and administration schedule of Rapalink-1 reported for the in vivo experiment was not correct. The error appeared both in the “Materials and Methods” and in the “Results” sections, where it is incorrectly reported as “1.5 mg/g [ … ] every 5 days” and “1.5 mg/g/6 days”, respectively. Figure 5C in the original article reported the correct administration schedule. A correction has been made to the “Materials and Methods” section, “Animals Maintenance and in vivo Experiment” sub-section.